Lineage Cell Therapeutics Inc. — Director's Dealing 2012

Apr 12, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-04-11

Reporting Person: LICHTINGER PEDRO (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-04-11	Common Shares, no par value	P	6250	$3.976	Acquired	6250	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Shares	$5.13	2016-06-30	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$5.45	2015-08-09	Common Shares (20000)	20000	Direct
Option to Purchase Common Shares	$3.45	2014-08-10	Common Shares (20000)	20000	Direct

Footnotes

F1: The price of $3.976 per share represents a weighted average of prices ranging from $3.975 to $3.98 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F2: Does not include shares that may be acquired upon the exercise of certain stock options.

F3: 5,000 options became exercisable on September 30, 2011; December 31, 2011; and March 31, 2012. The remaining 5,000 options will become exercisable on June 30, 2012 based upon continued service on the board of directors.

F4: 5,000 options became exercisable on September 30, 2010; December 31, 2010; March 31, 2011; and June 30, 2011.

F5: 5,000 options became exercisable on September 30, 2009; December 31, 2009; March 31, 2010; and June 30, 2010.